Brokers Offer Predictions for OS Therapies Q3 Earnings

OS Therapies Incorporated (NYSEAMERICAN:OSTX) – Analysts at Brookline Capital Markets boosted their Q3 2026 earnings estimates for OS Therapies in a research report issued to clients and investors on Tuesday, September 8th. Brookline Capital Markets analyst K. Raja now expects that the company will earn ($0.16) per share for the quarter, up from their previous forecast of ($0.19). The consensus estimate for OS Therapies’ current full-year earnings is ($0.77) per share. Brookline Capital Markets also issued estimates for OS Therapies’ Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.75) EPS, FY2027 earnings at ($0.22) EPS, FY2028 earnings at ($0.10) EPS, FY2029 earnings at $0.16 EPS and FY2030 earnings at $0.24 EPS.

Other equities analysts also recently issued research reports about the company. Roth Capital assumed coverage on OS Therapies in a report on Thursday, July 9th. They set a “buy” rating and a $7.00 price target on the stock. Lake Street Capital reduced their price objective on shares of OS Therapies from $14.00 to $13.00 and set a “buy” rating for the company in a research note on Tuesday, May 19th. Finally, Zacks Research raised shares of OS Therapies from a “strong sell” rating to a “hold” rating in a report on Thursday, June 4th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $13.33.

OS Therapies Stock Performance

Shares of OSTX stock opened at $1.82 on Friday. The stock’s 50 day simple moving average is $1.62 and its 200 day simple moving average is $1.62. OS Therapies has a twelve month low of $1.15 and a twelve month high of $2.35. The company has a market capitalization of $83.96 million, a price-to-earnings ratio of -1.67 and a beta of -0.68.

OS Therapies (NYSEAMERICAN:OSTX) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.20) earnings per share for the quarter.

Institutional Trading of OS Therapies

Several hedge funds have recently added to or reduced their stakes in OSTX. Millennium Management LLC acquired a new position in OS Therapies during the 3rd quarter valued at $183,000. Two Sigma Investments LP acquired a new stake in OS Therapies in the 3rd quarter worth $169,000. Geode Capital Management LLC increased its holdings in shares of OS Therapies by 31.1% during the 4th quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock worth $344,000 after purchasing an additional 58,350 shares during the period. Virtu Financial LLC increased its holdings in shares of OS Therapies by 252.0% during the 3rd quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock worth $149,000 after purchasing an additional 54,269 shares during the period. Finally, XTX Topco Ltd acquired a new position in shares of OS Therapies during the second quarter valued at about $63,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.